Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Colm Keane, Nada Hamad, Allison Barraclough, Yoo Y. Lee, Dipti Talaulikar, Matthew Ku, Joel Wight, Maciej Tatarczuch, Fiona Swain, Gareth P. Gregory

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Primary central nervous system lymphoma is a clinicopathological disease entity that accounts for 1% of all non-Hodgkin lymphoma (NHL). Advanced patient age, adverse disease biology and complexities of diagnosis and treatment render outcomes markedly inferior to systemic NHL. Despite this, an increasing evidence base, including limited randomised controlled clinical trial data, is informing optimal therapeutic strategies with methotrexate-based induction chemotherapy schedules and intensified consolidation in selected patients. This practice statement represents an evidence-based review of the literature and has been devised to assist healthcare professionals in the diagnosis and management of this disease.

Original languageEnglish
Number of pages9
JournalInternal Medicine Journal
DOIs
Publication statusAccepted/In press - 2022

Keywords

  • central nervous system
  • chemotherapy
  • CNS
  • lymphoma
  • PCNSL

Cite this